Human Primary Diabetic Pulmonary Vein Smooth Muscle Cells
Quick Actions
Product Overview
Description
Primary Smooth Muscle Cells derived from the Pulmonary Veins of human patients diagnosed with diabetes mellitus, characterized by specific alterations in their cellular function and behavior due to the disease. These cells are used for research into the effects of diabetes on vascular health and may play a role in understanding complications related to pulmonary circulation.
Guarantee expansion for a minimum of 2-5 population
doublings.
IMPORTANT: Quality warranty requires use of NeoBioPharma media. Biohazardous material despite negative pathogen testing. Quality claims must be reported within 1 month.
Key Features
Catalog Number: NBPDS010
Product Format: Frozen
Vial Cell Number: > 5x10[5] cells/vial
Passage:1(P1)
Storage: Liquid Nitrogen, Vapor Phase
Intended Use: Research use only (RUO)
Marker Expression:
Positive for Alpha Smooth Muscle Actin .
Positive for Desmin.
Positive for Calponin and SM22 (specific SMC markers).
Negative for von Willebrand Factor (vWF) / CD31 (to confirm absence of endothelial cells).
Negative for Cytokeratin (to confirm absence of epithelial cells).
Quick Facts
Product Type
Human Type II Diabetes Endothelial Cells
Viability
>95% viable (Trypan Blue exclusion)
Applications
Diabetic Vascular Remodeling: Investigating how h…
Availability
In Stock • Global Shipping
Technical Specifications
Primary Applications
Applications & Use Cases
Primary Applications
Diabetic Vascular Remodeling: Investigating how high glucose alters the growth and death rates of venous smooth muscle. Signal Transduction: Studying pathways like PKC (Protein Kinase C)
Suitable for diabetic vascular remodeling: investigating how high glucose alters the growth and death rates of venous smooth muscle. signal transduction: studying pathways like pkc (protein kinase c) studies and research applications
MAPK/ERK
Suitable for mapk/erk studies and research applications
or advanced glycation end-products (AGEs) and their receptor (RAGE) in a diabetic context. Pharmacological Testing: Screening new drugs aimed at preventing vascular stiffness or treating pulmonary hypertension specifically in diabetic patients. Inflammation: Examining the interaction between hyperglycemia and inflammatory cytokine production in the vessel wall.
Suitable for or advanced glycation end-products (ages) and their receptor (rage) in a diabetic context. pharmacological testing: screening new drugs aimed at preventing vascular stiffness or treating pulmonary hypertension specifically in diabetic patients. inflammation: examining the interaction between hyperglycemia and inflammatory cytokine production in the vessel wall. studies and research applications
Research Areas
In Vitro Studies
Cell culture and screening applications
Molecular Biology
Gene expression & signaling studies
Drug Discovery
Screening & validation studies
Disease Modeling
Pathophysiology research
Support & Resources
Technical Support
Our experts are available for technical questions and protocol assistance.
Contact Support
